Ahmed Mostafa

The recent spillover of highly pathogenic (HP) H5N1 clade 2.3.4.4b into dairy cattle and other mammalian species has been concerning. Vaccine candidates that can be rapidly synthesized and implemented are key countermeasures for protecting the human population against emerging pathogens. Here we examine the use of a pH1N1 virus lacking the genetic material for hemagglutinin (HA), limiting the infection to a single cycle (sciIAV) or Cobalt lipid-porphyrin nanoparticles decorated with neuraminidase (NA) of HPAI H5N1 (N1-CoPoP) as vaccine candidates. C57BL/6 mice that were inoculated intranasally with a single dose of pH1N1 sciIAV did not differ in serum NA antibody compared to uninoculated mice. However, mice that were inoculated intramuscularly with the N1-CoPoP alone or in combination with pH1N1 sciIAV had increased N1 IgG antibodies. Upon lethal challenge with HPAIV H5N1, all mice inoculated with either pH1N1 sciIAV or N1-CoPoP were protected from weight loss, unlike unvaccinated mice with substantial body weight losses that succumb to viral infection between 7 and 10 days post infection (dpi). Both pH1N1 sciIAV and N1-CoPoP immunization minimized viral infection such that only one mouse receiving pH1N1 sciIAV had detectable viral titer in the lungs at 4 dpi. By 6 dpi, no mouse inoculated with pH1N1 sciIAV and/or N1-CoPoP had detectable virus in nasal turbinates, lungs or the brain, unlike the high viral titers found in uninoculated mice. Both pH1N1 sciIAV and N1-CoPoP were protective and should be investigated further as alternative vaccine candidates.

Reporter-expressing recombinant influenza A viruses (IAVs) have emerged as powerful tools for studying viral infection, host–pathogen interactions, and the identification and characterization of prophylactic and/or therapeutic countermeasures for the treatment of IAV infections. By incorporating a reporter gene, such as fluorescent, recombinase, or luciferase proteins, into the viral genome, these genetically engineered recombinant IAVs enable real-time visualization and quantification of infection in vitro , ex vivo , and in vivo to detect the presence of IAV in infected cells or animal models of infection. Among the various approaches to express reporter genes from the viral genome, fusion of fluorescent or luciferase proteins to the C-terminus of the non-structural 1 (NS1) protein has been successfully used to generate replication-competent reporter-expressing IAVs. This minireview summarizes the strategies used to generate IAV-expressing reporter genes, particularly from the non-structural (NS) viral segment 8, and their use in real-time tracking of viral replication and pathogenesis. These replication-competent reporter-expressing IAVs also provide an efficient tool for high-throughput screening (HTS) of novel anti-IAV therapeutics. We also discuss the advantages and limitations of current fluorescent and luciferase reporter-expressing IAVs to track viral infections in cultured cells and/or animal models, and provide perspectives on future directions in this rapidly advancing field.

Since its emergence in 2020, multiple genotypes of the H5N1 clade 2.3.4.4b have been identified, with B3.13 and D1.1 emerging in the USA as two major and concerning genotypes. However, their relative pathogenicity and transmissibility in mammals have not been fully elucidated. We compared the pathogenicity and transmissibility of the first two human H5N1 clade 2.3.4.4b cases caused by B3.13 in Texas (A/Texas/37/2024; HPhTX B3.13) and D1.1 in Louisiana (A/Louisiana/12/2024; HPhLA D1.1) in a ferret model of infection and transmission. HPhTX B3.13 infection resulted in more severe clinical disease and enhanced viral shedding, with evidence of increased transmission relative to HPhLA D1.1. Histopathological analysis revealed more extensive lung pathology in animals infected with HPhTX B3.13, consistent with increased viral loads and inflammatory responses. Importantly, both genotypes showed no significant differences in reactivity to ferret sera raised against candidate vaccine virus (CVV) strains, receptor binding properties, or neuraminidase (NA) activity and thermostability. Whole-genome sequencing revealed no adaptive mutations in HPhTX B3.13 following infection or transmission. In contrast, HPhLA D1.1 showed rapid acquisition of the mammalian-adaptive mutation E627K in infected ferrets and both E627K and Q194K in the only fatal contact animal. Both mutations were associated with enhanced polymerase activity and computational analyses suggested that they enhance interactions with the mammalian host factors ANP32A and B. Our findings indicate that B3.13 is already well adapted for mammalian infection and transmission whereas D1.1 retains evolutionary potential through the rapid acquisition of adaptive mutations, highlighting important genotype-specific differences relevant to zoonotic risk assessment and pandemic preparedness.

Marine mammals, particularly seals, are susceptible to both avian and human influenza A viruses (IAVs), making them potential intermediates for zoonotic virus emergence. In recent decades, repeated transmissions of avian influenza viruses (AIVs) from wild aquatic birds, their natural reservoir, have caused significant mortality in seals. Defining the molecular determinants of viral adaptation in marine mammals, and their implications for replication in human cells, is therefore essential. The non-structural protein 1 (NS1) of AIV, a key antagonist of the interferon (IFN) response, plays a central role in host adaptation. Here, we analyzed NS1 proteins from seal influenza viruses (H3, H4, H5, H7, and H10 subtypes) and their closest avian relatives isolated between 1980 and 2023, and evaluated their function in seal, avian, and human cells. Phylogenetic analysis confirmed multiple bird-to-seal transmission events. Seal-derived NS1 proteins generally contained few strain-specific amino acid substitutions and showed comparable expression and IFN antagonism to their avian precursors. A notable exception was the seal H10N7 virus isolated in 2014 in Northeastern Europe, which harbored three previously uncharacterized substitutions at NS1 amino acid residues 94, 104, and 171. These amino acid substitutions markedly altered NS1 properties to enhance protein stability, suppress IFN induction, mediate host transcription shut-off, and increase polymerase activity in human cells, without affecting NS1 expression or reducing virus replication in avian cells. Overall, these results reveal how NS1 undergoes host-specific functional evolution following avian-to-seal transmission and provide mechanistic insight into the adaptation of influenza A viruses to mammalian hosts. IMPORTANCE: Avian influenza viruses (AIVs) circulate naturally in wild aquatic birds but occasionally infect mammals, including seals, where they can cause severe outbreaks. Seals are of particular concern because they can harbor both avian and human influenza viruses, creating opportunities for reassortment and the emergence of novel zoonotic strains. Understanding how AIVs adapt to mammalian hosts is therefore critical for anticipating and mitigating future influenza threats. Here, we investigated the role of the NS1 protein, a key viral factor that suppresses host immune responses, in seal-derived AIVs. Overall, NS1 expression and function were conserved across different subtypes and host cells. However, we identified unique amino acid substitutions in the NS1 of a seal H10N7 virus that enhanced protein stability, interferon antagonism, and viral adaptation in human cells. These findings illustrate how minor changes in NS1 protein can drive host adaptation and underscore the need for continued surveillance of AIVs in seals.

The discovery of a new antiviral drug specifically targeting SARS-CoV-2 would require considerable time and effort. Repositioning drugs that are already used for other viral infections is a valuable approach. Remdesivir is the first antiviral treatment approved by the Food and Drug Administration (FDA) for COVID-19. Nitazoxanide is a broad-spectrum anti-infective agent that has been suggested for repurposing in COVID-19 treatment. Recent research has demonstrated the synergistic anti-SARS-CoV-2 antiviral activity of Remdesivir when combined with Nitazoxanide. Moreover, Daclatasvir is an FDA-approved antiviral for managing chronic HCV infection, and its potential use in treating COVID-19 has been reported. Piroxicam is an FDA-approved anti-inflammatory with some clinical evidence supporting its application for COVID-19. There is no evidence for exploiting the anti-SARS-CoV-2 activity of Daclatasvir when combined with Piroxicam. We were able to demonstrate the enhanced anti-SARS-CoV-2 activity of the Remdesivir-Nitazoxanide and Daclatasvir-Piroxicam binary mixtures in Vero-E6 cells. In addition, we were able to develop a simple HPLC methodology for the concurrent determination of the two analytes of each binary mixture (Remdesivir-Nitazoxanide mixture and Daclatasvir-Piroxicam mixture) in both pure form and in human plasma using non-complicated, widely available analytical instruments. The proposed method is simple, accurate, quick, and sensitive. No drug interactions were observed in the tested binary mixtures.

Balanites aegyptiaca (L.) Delile, commonly known as desert date, is a multipurpose medicinal plant widely used in traditional African and Middle Eastern medicine. Various parts of the plant, particularly the seeds and fruit, are used to treat infections, gastrointestinal disturbances, parasitic diseases, and inflammation. Its rich composition of bioactive compounds suggests a potential role in managing microbial infections in veterinary contexts, including poultry farming. The current study aimed to evaluate the in vitro biological activities and for the first time the in vivo antimicrobial efficacy of fruit extract, seed oil and its nanoemulsion against Escherichia coli O78 and Clostridium perfringens type A in experimentally infected broiler chickens.

1. Newcastle disease virus (NDV), responsible for Newcastle disease (ND), is an avian virus found across several bird species [1]. It can induce highly contagious respiratory, neurological, and gas...

The continuous emergence of variants of concern (VoC) represent a significant challenge to effectively control SARS-CoV-2. Although FDA-approved vaccines and antivirals have been successfully developed and implemented for the prophylactic and therapeutic intervention of SARS-CoV-2 infection, recent VoC could escape protection garnered by previous vaccine and antiviral approaches. Determining the efficacy of prophylactics and/or therapeutics against recent VoC will assist in efficiently controlling currently circulating SARS-CoV-2 strains. We used our previously described bacterial artificial chromosome (BAC)-based reverse genetics approach for Omicron BA.5 to generate a recombinant SARS-CoV-2 BA.5 encoding a fusion of ZsGreen to Nanoluciferase (rBA.5 ZsG-Nluc) from the locus of the viral nucleocapsid (N) protein separated by the porcine teschovirus-1 (PTV-1) 2A proteolytic cleavage site. The rBA5 ZsG-Nluc replicates to levels comparable to recombinant BA.5 wild-type (rBA.5 WT) and expresses high levels of ZsG and Nluc in cultured cells. This facilitates tracking viral infection and the identification of antivirals and neutralizing antibodies (NAbs) with EC ₅₀ and NT ₅₀ values, respectively, similar to those obtained with rBA.5 WT. Importantly, in K18 hACE2 mice, rBA.5 ZsG-Nluc retains the same pathogenicity and ability to replicate in the lungs of infected mice as rBA.5 WT. Using rBA.5 ZsG-Nluc, we detected Nluc activity systemically and Nluc and ZsG expression in the lungs of infected mice using an in vivo imaging system (IVIS). Our results demonstrate the feasibility of using rBA.5 ZsG-Nluc to track viral infections and identify prophylactics and therapeutics against recent SARS-CoV-2 VoC in vitro , ex vivo , and in vivo . IMPORTANCE: SARS-CoV-2, the causative virus of the COVID-19 pandemic, is continually evolving to escape immunity acquired by previous natural infections or vaccinations. Moreover, recent SARS-CoV-2 variants of concern (VoC) have acquired antiviral resistant mutations to FDA-approved drugs. The emergence of these VoC highlights the importance of identifying new prophylactics and therapeutics against currently circulating SARS-CoV-2 strains. We generated a recombinant bireporter Omicron BA.5 SARS-CoV-2 (rBA.5 ZsG-Nluc) that expresses reporter proteins, which are useful for cellular and whole animal studies and has similar viral replication and pathogenicity to a wild-type (WT) recombinant Omicron BA.5 SARS-CoV-2 (rBA.5 WT). In K18 hACE2 mice, rBA.5 ZsG-Nluc infection can be tracked systemically or in the lungs of infected mice using an in vivo imaging system (IVIS). We establish a proof-of-concept platform of rBA.5 ZsG-Nluc in combination with an ancestral SARS-CoV-2 strain expressing mCherry to simultaneously identify antivirals and neutralizing antibodies against original and recent SARS-CoV-2 strains.

The remaining unacceptably high mortality of influenza-induced acute respiratory distress syndrome underscores the urgent need to identify key cellular drivers of host responses. Endothelial cells (ECs) are increasingly recognized for their immunomodulatory roles, but whether they function as antigen-presenting cells (APCs) following respiratory viral infection remains unknown. Here, we show that influenza A virus H1N1 restrictively infects pulmonary microvascular ECs (PMVECs) during late-stage acute lung injury, triggering robust MHC class I (MHC-I) upregulation in vitro, in vivo, and in ex vivo human precision-cut lung slices. Infected PMVECs present H1N1 antigens via MHC-I and co-stimulatory CD40 to lung-resident CD8⁺ T cells, driving their proliferation and effector function (Granzyme B, IFNγ) to promote viral clearance and resolve inflammation. This process is IFNγ-dependent and STAT1-regulated, forming a positive feedback loop that enhances PMVEC antigen presentation and CD8⁺ T cells activation. By contrast, the emerging H5N1 (A/Texas/37/2024) infect pulmonary ECs earlier and more broadly but elicits weaker pulmonary EC-driven CD8 + T cell responses, potentially contributing to its higher pathogenicity. These findings reveal PMVECs as active APCs in antiviral defense and highlight new avenues for immunotherapeutic intervention.